Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exclusive: U.S. Chamber Lobbies Against China Drug Registration Revisions That Would Favor Local Generics

This article was originally published in PharmAsia News

Executive Summary

The U.S. Chamber of Commerce is lobbying China FDA over its recent draft drug registration regulations, which would allow approval of generics while an originator’s patent is still valid. Big pharma could face faster and stronger generic competition in China if CFDA finalizes the regulations without revision.

Advertisement

Related Content

China To Implement New Regulations For Patent Law; Companies Should Set Up Inventor Reward Policy To Prepare For Changes

Topics

Advertisement
UsernamePublicRestriction

Register

SC086233

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel